

Physiogenex extends collaboration with Central Lab. Animal Inc

Labège, France ; Seoul, Korea ; April, 28 2014 - Physiogenex, a leading preclinical contract research organization specializing in metabolic diseases and complications, has extended the relationship started in 2012 with Central Lab. Animal Inc, a renowned Korean company with long term experience in bioservices, such as experimental rodents supply to pharmaceutical companies.

Under this agreement, Central Lab. Animal Inc will represent Physiogenex and market services on the South Korean biopharmaceutical market.

"We are delighted to extend our regional relationship with Central Lab. Animal Inc and look forward to provide Korean pharmaceutical companies with our expertise and services to speed up the development of their compounds," commented Thierry Sulpice, CEO, CSO, Physiogenex.

About Central Lab. Animal Inc

Central Lab. Animal, Inc . is the expert supplier of experimental rodents, constantly providing best quality bioservices to researchers. Based on its experience acknowledged by pharmaceutical companies, Central Lab. Animal, Inc. will efficiently provide CRO services with Physiogenex.

Find out more about Central Lab. Animal Inc and the services offered at www.labanimal.co.kr

About Physiogenex

Physiogenex is a leading research organization providing non clinical services in metabolic disorders and complications. We offer *in vivo* translational diseases models as well as *ex vivo* assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and cardiovascular complications.

Physiogenex leads the Cardiometabolic hub, a network of preclinical CRO specializing in metabolic and cardiovascular diseases. This hub includes Cardiomedex and Bêtagenex.

Please visit our website for more information at www.physiogenex.com

Contact information:
Cecile Durand
+33 5 61 28 70 40
www.physiogenex.com